Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Publisher
European Heart Journal - Cardiovascular Pharmacotherapy(1)
European Heart Journal - Quality of Care and Clinical Outcomes(1)
New England Journal of Medicine(1)
Trials(1)
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusRationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery
ArticleAbstract: Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and asPalabras claves:Cardiovascular Complications, noncardiac surgery, Perioperative bleeding, Perioperative hypotension, Randomized controlled trial, Tranexamic acidAutores:Abubakirov M., Aguado H.J., Alfonsi P., Amir M., Astrakov S.V., Ayad S., Balasubramanian K., Bangdiwala S.I., Belley-Cote E.P., Bhatt K., Biccard B.M., Borges F.K., Chan M.T.V., Cheong C.C., Conen D., Copland I., de Nadal M., Devereaux P.J., Duceppe E., Efremov S., Eikelboom J.W., Fleischmann E., Garg A.X., Gross P.L., Guyatt G.H., Iglesisas P.P., Jayaram R., Kirov M., Kleinlugtenbelt Y.V., Kurz A., Lamy A., Landoni G., Leslie K., Likhvantsev V.V., Lomivorotov V.V., Ma José Martínez Zapata, Marcucci M., McGillion M.H., McIntyre W., Meyhoff C.S., Ofori S.N., Painter T.W., Parlow J.L., Patel A., Petit S., Polanczyk C.A., Rao M., Richards T., Roshanov P.S., Ruetzler K., Schmartz D., Sessler D.I., Short T.G., Spence J., Srinathan S., Stillo D., Szczeklik W., Tandon V., Torres D., VanHelder T., Vincent J., Wang C.Y., Wang M.K., Whitlock R.P., Wittmann M., Wu W.K.K., Xavier D., Yusuf S.Fuentes:scopusRivaroxaban with or without aspirin in stable cardiovascular disease
ArticleAbstract: BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effePalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhagirath V., Bhatt D.L., Bogaty P.M., Bosch J.J., Botto F., Branch K.R.H., Bruns N.C., Cairns J., Carlos Ernesto Peñaherrera, Casanova A., Catanese L., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DeMets D., Deng E., DIaz R., Donato Magno J., Edgar B. Rodas, Eikelboom J.W., Ertl G., Fabbri G., Felix Camilo, Fox K.A.A., Gabizon I., Gosselin G., Goto S., Guzik T.J., Ha J., Halon D., Hart R.G., Heldmann M., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamelas P.M., Lamy A., Lanas F., Lauw M., Leong D.P., Leong Y., Lewis B.S., Liang D., Liang Y., Liu L., Lonn E.M., Lutay Y., Maggioni A.P., Maly M., María José Paucar, Metsarinne K.P., Mikulik R., Misselwitz F., Moayyedi P., Momomura S.I., Nayar S., Ng K., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Perera K., Piegas L.S., Pirvu O., Pogosova N., Prins M., Probstfield J.L., Ramsay T., Ronner E., Rouleau J.L., Rydén L.E., Sato S., Schumi J., Sharma M., Shestakovska O., Shirley Guamán, Silvia Cáceres, Sleight P., Smyth A., Sokolova E., Steg P.G., Stoerk S., Störk S., Thabane L., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Wiendl M., Winkelmann B., Yan Duarte, Yang X., Yufereva Y., Yusoff K., Yusuf S., Zhu J.Fuentes:scopusThe cost implications of a polypill for primary prevention in the TIPS-3 trial
ArticleAbstract: Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesPalabras claves:Cardiovascular disease, cost analysis, Polypill, Primary PreventionAutores:Dans A.L., Gamra H., Gao P., Joseph P.G., Lamy A., Pais P., PATRICIO LOPEZ -JARAMILLO, Santoso A., Talukder S.H., Tong W., Walli-Attaei M., Xavier D., Yusuf S.Fuentes:googlescopus